Related Experiment Video
Updated: Aug 6, 2026

Deacetylation Assays to Unravel the Interplay between Sirtuins (SIRT2) and Specific Protein-substrates
Published on: February 27, 2016
Sultams as Dual Inhibitors of Human Carbonic Anhydrase and Thioredoxin Reductase
Aleksandrs Pustenko1, Raitis Bobrovs1, Venkatesan Saravanan2
1Latvian Institute of Organic Synthesis, Riga, Latvia.
Abstract:
Cancer remains a leading cause of mortality, often complicated by drug resistance arising from single-target therapies. Dual inhibitors that simultaneously target multiple cancer-related defense mechanisms offer a promising strategy to overcome these limitations. Herein, we report the design, synthesis, and biological evaluation of a series of sultam-based N-acyl derivatives (8a-k and 9a-k) as potential dual inhibitors of thioredoxin reductase (TrxR1) and tumor-associated carbonic anhydrases (CA IX and XII). TrxR1 screening identified a few active compounds, with inhibitory potency strongly influenced by the type and orientation of substituents. CA inhibition assays revealed pronounced selectivity for CA IX/XII, while off-target isoforms CA I and CA II remained unaffected. These findings highlight the potential of sultam derivatives as dual-targeting anticancer agents and provide a foundation for further optimization toward selective, multi-pathway cancer therapy.
Insights
New sultam-based compounds show promise as dual inhibitors targeting thioredoxin reductase (TrxR1) and tumor-associated carbonic anhydrases (CA IX/XII) to combat cancer drug resistance.
Area of Science:
- Medicinal Chemistry
- Oncology
- Biochemistry
Background:
- Cancer drug resistance limits single-target therapies.
- Dual inhibitors offer a strategy to overcome resistance by targeting multiple pathways.
Purpose of the Study:
- Design, synthesize, and evaluate novel sultam-based N-acyl derivatives.
- Assess their potential as dual inhibitors of thioredoxin reductase (TrxR1) and tumor-associated carbonic anhydrases (CA IX and XII).
Main Methods:
- Synthesis of sultam-based N-acyl derivatives (compounds 8a-k and 9a-k).
- In vitro screening for thioredoxin reductase (TrxR1) inhibition.
- Carbonic anhydrase (CA) inhibition assays, including selectivity profiling against off-target isoforms (CA I and CA II).
Main Results:
- Several compounds exhibited activity against TrxR1, with potency dependent on substituent type and orientation.
- The derivatives displayed significant selectivity for tumor-associated CA IX and XII over non-tumor isoforms CA I and II.
- No significant inhibition was observed for off-target isoforms CA I and CA II.
Conclusions:
- Sultam-based N-acyl derivatives show potential as dual-targeting anticancer agents.
- These compounds effectively inhibit TrxR1 and selectively target CA IX/XII.
- Further optimization could lead to novel selective, multi-pathway cancer therapies.
Related Concept Videos
Sulfur Assimilation
Preparation and Reactions of Thiols
Phase II Reactions: Miscellaneous Conjugation Reactions
A key example involves the conjugation of cyanide ions, which impair cellular respiration and alter hemoglobin into non-oxygen-carrying cyanmethemoglobin. To neutralize this threat, a sulfur atom from thiosulphate is transferred to the cyanide ion, catalyzed by the enzyme rhodanese, resulting in an inactive compound called thiocyanate. The production of...
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Drug Metabolism: Phase II Reactions
Phase II Reactions: Sulfation and Conjugation with α-Amino Acids
